Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology

Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology

Mantle cell lymphoma artificial intelligence prognostic index using hematoxylin and eosin histology

https://www.nature.com/articles/s41375-026-03036-8

Publish Date: 2026-07-07 04:04:00

Source Domain: www.nature.com

  • Fu S, Wang M, Lairson DR, Li R, Zhao B, Du XL. Trends and variations in Mantle cell lymphoma incidence from 1995 to 2013: a comparative study between Texas and National SEER areas. Oncotarget. 2017;8:112516–29.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo IB, de O, Berti E, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720–48.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Morello L, Rattotti S, Giordano L, Jerkeman M, van Meerten T, Krawczyk K, et al. Mantle cell lymphoma of mucosa-associated lymphoid tissue: a European mantle cell lymphoma network study. Hemasphere. 2020;4:e302.

    Article 
    PubMed 

    Google Scholar 

  • Navarro A, Beà S, Jares P, Campo E. Molecular pathogenesis of Mantle cell lymphoma. Hematol Oncol Clin North Am. 2020;34:795–807.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar 

  • Jiang L, Ladetto M, Hermine O, Kluin-Nelemans JC, Walewski J, Doorduijn J, et al. Marked survival gains in patients ≤ 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020. Haematologica. 2025.

  • Dreyling M, Doorduijn J, Giné E, Jerkeman M, Walewski J, Hutchings M, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024;403:2293–306.

    Article 
    CAS 
    PubMed 

    Google Scholar 

  • Shah NN, Colina AS, Johnson BD, Szabo A, Furqan F,…

  • Source